BOSTON, Aug. 18 The Center for Business Intelligence (CBI), a division of Advanstar Communications, is pleased to host their September Congress taking place at the Courtyard Downtown, Philadelphia, PA, on September 23-24, 2009. "In the current economic climate, with heightened M & A activity in the pharma sector and the prospect of major health reform, risk management and governance has become more critical," says Sharon Langan, Senior Program Manager, CBI.
Advertisement
Not only has CBI engaged the participation of the Risk Assessment Office at the U.S. Securities and Exchange Commission and the Corporate Ratings Group at Standard & Poor's, but also 10 pharmaceutical company presenters offering case studies, panel discussion and high-level discussions on internal audit and pharma compliance activities that drive organizational value and strategically manage risk in the changing economy.
Advertisement
Hear presentations from companies including:
This prestigious Congress is the only platform specifically designed for the pharmaceutical and biotech industries and has since inception, benefitted over 500 attendees.
For more information on this event, please visit http://www.cbinet.com/erm. If you would like to apply for a press pass, please contact Monali Shah of CBI at 339.298.2285.
About CBI:
A subsidiary of Advanstar Communications, CBI Research, Inc. offers pharmaceutical and healthcare conferences that serve senior executives and government officials by providing a unique platform for highly focused content and ideal networking opportunities with senior policy- and decision-makers. CBI events provide you with concrete, real-life examples that you can begin to apply at your organization immediately for significant impact on costs and revenue. For more information, please visit http://www.cbinet.com.
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
-- Bristol-Myers Squibb -- Cephalon -- Eisai Pharmaceuticals -- Elan Pharmaceuticals, Inc. -- GlaxoSmithKline -- MedImmune, Inc. -- Par Pharmaceutical Companies Inc. -- sanofi-aventis Pharmaceuticals -- Shire Pharmaceutical
SOURCE CBI Research, Inc.
